Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.

@article{Coluccia2008ValidationOP,
  title={Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.},
  author={Addolorata Maria Luce Coluccia and Teresa Cirulli and Paola Neri and Domenica Mangieri and Maria Cristina Colanardi and Antonio Gnoni and Nicola di Renzo and Franco Dammacco and Pierfrancesco Tassone and Domenico Ribatti and Carlo B Gambacorti-Passerini and Angelo Vacca},
  journal={Blood},
  year={2008},
  volume={112 4},
  pages={1346-56}
}
Inhibition of multiple myeloma (MM) plasma cells in their permissive bone marrow microenvironment represents an attractive strategy for blocking the tumor/vessel growth associated with the disease progression. However, target specificity is an essential aim of this approach. Here, we identified platelet-derived growth factor (PDGF)-receptor beta (PDGFRbeta) and pp60c-Src as shared constitutively activated tyrosine-kinases (TKs) in plasma cells and endothelial cells (ECs) isolated from MM… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

Novel drugs in myeloma: harnessing tumour biology to treat myeloma.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer • 2011
View 12 Excerpts
Highly Influenced

AKT as a therapeutic target in multiple myeloma.

Expert opinion on therapeutic targets • 2014
View 7 Excerpts
Highly Influenced

New Insights in Anti-Angiogenesis in Multiple Myeloma

International journal of molecular sciences • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 53 references

Endothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myeloma.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2008

Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2006

Similar Papers

Loading similar papers…